Revision of PRECAUTIONS

Tirzepatide

July 20, 2023

Therapeutic category
Other hormone preparations

Non-proprietary name
Tirzepatide

Safety measure
PRECAUTIONS should be revised.
Revision in line with the Instructions for Electronic Package Inserts of Prescription Drugs, etc. PSEHB Notification No. 0611-1 by the Director-General of Pharmaceutical Safety and Environmental Health Bureau, MHLW, dated June 11, 2021 (New instructions):

Revised language is underlined.

<table>
<thead>
<tr>
<th>Current</th>
<th>Revision</th>
</tr>
</thead>
<tbody>
<tr>
<td>11. ADVERSE REACTIONS</td>
<td>11. ADVERSE REACTIONS</td>
</tr>
<tr>
<td>11.1 Clinically Significant Adverse Reactions</td>
<td>11.1 Clinically Significant Adverse Reactions</td>
</tr>
<tr>
<td>(N/A)</td>
<td>Anaphylaxis, angioedema</td>
</tr>
</tbody>
</table>

N/A: Not Applicable. No corresponding language is included in the current PRECAUTIONS.